1b0cc94a3b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
23 lines
No EOL
710 B
Markdown
23 lines
No EOL
710 B
Markdown
---
|
|
type: entity
|
|
entity_type: company
|
|
name: Orbicular Pharmaceutical Technologies
|
|
domain: health
|
|
status: active
|
|
founded: null
|
|
headquarters: null
|
|
website: null
|
|
tags: [generic-pharmaceuticals, semaglutide, GLP-1, formulation]
|
|
---
|
|
|
|
# Orbicular Pharmaceutical Technologies
|
|
|
|
Pharmaceutical formulation development company.
|
|
|
|
## Overview
|
|
|
|
Orbicular Pharmaceutical Technologies partnered with Apotex on the development of generic semaglutide injection that received first US FDA tentative approval.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-10** — Partnership with Apotex received first US FDA tentative approval for generic semaglutide injection (ANDA). Orbicular provided formulation development expertise for the generic version. |